Skip to main content
|

Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer

Short Title: EA2192/APOLLO


Enrollment Status: Recruiting

NCT #: NCT04858334

Specialty Area: Oncology

Condition Studied: Pancreatic Cancer

Age Groups: Adult; Older Adult

Phase: II


Study Information

Summary / Purpose

To determine whether maintenance therapy with olaparib improves disease-free survival compared to placebo in patients with resected pancreatic cancer and a BRCA1/2 or PALB2 mutation.

Study Type: Interventional
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 18+ years of age
  • Diagnosed with pancreatic ductal adenocarcinoma
  • Must have completed curative-intent therapy (surgery with or without chemotherapy/radiation)
  • Documented germline or somatic mutation in BRCA1, BRCA2, or PALB2
  • No evidence of disease recurrence at enrollment
  • Adequate organ and marrow function

What's Involved

Participation in the study will include:
  • Study medication given orally (either olaparib or placebo) once daily for up to 12 months
  • Standard follow-up after curative-intent therapy (surgery ± chemotherapy ± radiation)
  • Regular CT or MRI scans to monitor response to treatment
  • Blood tests to check your health and how the treatment is working
  • Questionnaires

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up